In this episode of Behind the Bell, Boundless Bio CEO Zachary Hornby speaks to how being publicly listed will help the company continue its work in exploring an area of cancer biology that has not previously been thoroughly researched.

Watch more of Behind the Bell on Nasdaq.com: https://www.nasdaq.com/news-and-insig...